LGALS9 and myeloid sarcoma: So far, CTLA-4–CD80/86, PD-1–PD-L1/2, TIGIT–CD112/155, TIM-3–galectin-9, and CD43/45–galectin-1 are the only immune inhibitory pathways involved in EAE amelioration with a strong genetic or functional correlation in MS [4, 24, 31, 38–41, 48].